Faculty Bibliography

An influential panel of the New York State Health Department is urging sweeping changes in the regulation of new fertility technologies, including more steps to reduce the incidence of multiple births. In a report issued today, the panel said doctors providing infertility treatments must think more about the babies born as a result and avoid treatments that are more likely to produce so-called high-order multiple births -- pregnancies of three, four or more babies who are far more prone to devastating problems such as retardation and blindness. Doctors should talk with patients in advance about the possible need to abort one or more fetuses in a high-order multiple pregnancy, the panel said. If an abortion is not an option for the patient, doctor and patient should consider other treatments, even if the chances of pregnancy are reduced

Two new studies reported in preliminary form Monday suggest that a second drug apparently can prevent breast cancer, at least in the short term. But this drug, raloxifene, did not appear to raise the risk of uterine cancer, a side effect of the first drug, tamoxifen, whose benefits were reported earlier this month. Raloxifene reduced the incidence of breast cancer by about half, roughly the same proportion as in the earlier study of tamoxifen, according to information made public on Monday by a national cancer organization. However, the raloxifene studies did not last as long as the tamoxifen study

Two new studies reported in preliminary form yesterday suggest that a second drug can apparently prevent breast cancer, at least in the short term. But this drug, raloxifene, did not appear to raise the risk of uterine cancer, a side effect of the first drug, tamoxifen, whose benefits were reported earlier this month. Raloxifene reduced the incidence of breast cancer by about half, roughly the same proportion as in the earlier study of tamoxifen, according to information made public yesterday by a national cancer organization. However, the raloxifene studies did not last as long as the tamoxifen study. In calling the new findings ''important and encouraging,'' the head of the National Cancer Institute, Dr. Richard D. Klausner, said they had led his institute to design a study directly comparing the benefits and risks of raloxifene and tamoxifen. The study, which is expected to begin later this year, was announced on April 6, when the cancer agency reported a 45 percent reduction in risk of breast cancer among tamoxifen users compared with those who took a dummy pill, or placebo

Two new studies reported in preliminary form on Monday suggest that a second drug apparently can prevent breast cancer, at least in the short term. But this drug, raloxifene, did not appear to raise the risk of uterine cancer, a side effect of the first drug, tamoxifen, whose benefits were reported earlier this month. Raloxifene reduced the incidence of breast cancer by about half, roughly the same proportion as in the earlier study of tamoxifen, according to information made public on Monday by a national cancer organization. But the raloxifene studies did not last as long as the tamoxifen study

Two new studies suggest that a second drug, raloxifene, apparently can prevent breast cancer. But raloxifene did not appear to raise the risk of uterine cancer, a side effect of tamoxifen, whose benefits were reported this month. Raloxifene halved the incidence of breast cancer, roughly the same proportion as in the earlier study of tamoxifen, according to information made public Monday by a national cancer organization. However, the raloxifene studies did not last as long as the tamoxifen study

Two new studies suggest that a second drug apparently can prevent breast cancer, at least in the short term. But the drug, raloxifene, did not appear to raise the risk of uterine cancer, a side effect of the first drug, tamoxifen, whose benefits were reported earlier this month. Raloxifene reduced the incidence of breast cancer by about half, roughly the same proportion as in the earlier study of tamoxifen, according to information made public yesterday by a national cancer organization. However, the raloxifene studies did not last as long as the tamoxifen study. In calling the new findings 'important and encouraging,' the head of the National Cancer Institute, Dr. Richard Klausner, said that they have led his institute to design a study directly comparing the benefits and risks of raloxifene and tamoxifen. The study, which is expected to begin later this year, was announced April 6, when the cancer agency reported a 45 percent reduction in risk of breast cancer among tamoxifen users compared to those who took a a placebo, or dummy pill. 1

Two new studies reported in preliminary form Monday suggest that a second drug apparently can prevent breast cancer, at least in the short term. But this drug, raloxifene, did not appear to raise the risk of uterine cancer, a side effect of the first drug, tamoxifen, whose benefits were reported earlier this month. Raloxifene reduced the incidence of breast cancer by about half, roughly the same proportion as in the earlier study of tamoxifen, according to information made public Monday by a national cancer organization. However, the raloxifene studies did not last as long as the tamoxifen study. In calling the new findings 'important and encouraging,' the head of the National Cancer Institute, Dr. Richard Klausner, said that they have led his institute to design a study directly comparing the benefits and risks of raloxifene and tamoxifen. The study, which is expected to begin later this year, was announced April 6, when the cancer agency reported a 45 percent reduction in risk of breast cancer among tamoxifen users compared to those who took a dummy pill, or placebo

WHEN AIDS was first recognized in New York in 1981, it was not as a viral infection but as Kaposi's sarcoma, a rare type of cancer affecting the skin and internal organs. After realizing that AIDS was a new disease, doctors then noticed that two other unusual types of cancer -- non-Hodgkins lymphoma and primary lymphoma of the brain -- also occurred with unusual frequency among people with H.I.V., the AIDS virus. Because H.I.V. suppresses the immune system and most AIDS-related cancers are strongly associated with viruses, scientists saw in the tragedy of the AIDS epidemic an extraordinary opportunity to study the interplay of viruses, an impaired immune system and the development of cancer. In a way, AIDS research was an extension of the war on cancer that the Government declared in 1971. Researchers are broadening their understanding of the number and types of viruses that might play a role in cancer. Now, for example, there is increasing evidence of a link between Kaposi's sarcoma and a recently discovered herpes virus known as H.H.V.-8. Researchers also report an apparent decline in two types of AIDS-related cancers after the introduction of newer anti-H.I.V. combination drug therapy

For the first time, a drug has been shown to prevent breast cancer among women at high risk for the disease, a jubilant group of federal health officials said Monday. Women who took the drug, tamoxifen, had 45 percent fewer cases of breast cancer than a group of women who took a dummy pill or placebo. The drug helped all age groups in a large study, they said. The health officials said the study results are historic and may lead to development of drugs to prevent other cancers. But because tamoxifen also carries risks of life-threatening adverse effects, such as cancer of the uterus and blood clots that migrate to the lungs from veins in the legs, women were cautioned not to rush to demand the drug before statisticians and other experts do further analyses, so that doctors can interpret the findings for individual women